Final results from IMPROVE: A randomized, controlled, open-label, cross-over phase IV study to determine the patients’ preference for either combined endocrine therapy (exemestane plus everolimus) or immunochemotherapy (capecitabine plus bevacizumab) as first line treatment for advanced HR+/HER2- breast cancer.

Kurbacher, C., Söling, U., Hahn, A., Chiabudini, M., Maintz, C., Rieger, L., Falkenstein, J., Runkel, E., Potthoff, K., Decker, T., 2019.

Cancer Res 79 (4 Supplement)(P6-21–11). doi:10.1158/1538-7445.SABCS18-P6-21-11